Details
1. A tablet upgraded proprietary technique from the existing medicine through a new technique( Patent file No.: 10-2006-0007059)
2. The excellent therapeutic effect
1)Composition
Tolterodine L-tartrate 4mg/tab.
2)Indications
Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder syndrome.
3)Dosage & Administration
The recommended dose is 4mg once daily except in patients with impaired liver function or severely impaired renal function for whom the recommended dose is 2mg once daily. In case of troublesome side-effects the dose may be reduced from 4 mg to 2 mg once daily. The sustained release tablet can be taken with or without food and must be swallowed as a whole.
4)Package
30T